ASO Author Reflections: A Perspective on Nonsentinel Axillary Lymph Node Status in Sentinel Lymph Node-Positive Early Breast Cancer After Primary Systemic Therapy and ALND-Predict

Isaac Cebrecos^#^{1

2}, Eduard Mension^#¹, Maria Vidal^#^{2

3

4}, Francesco Schettini^#^{5

6

7}

Affiliations

¹ Clinic Institute of Gynecology, Obstetrics and Neonatology, Hospital Clinic of Barcelona, Barcelona, Spain.
² Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.
³ Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
⁴ Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
⁵ Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain. schettini@clinic.cat.
⁶ Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain. schettini@clinic.cat.
⁷ Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. schettini@clinic.cat.

^# Contributed equally.

Comment

Isaac Cebrecos et al. Ann Surg Oncol. 2023 Sep.

. 2023 Sep;30(9):5705-5706.

doi: 10.1245/s10434-023-13297-7. Epub 2023 Feb 23.

Isaac Cebrecos^#^{1

2}, Eduard Mension^#¹, Maria Vidal^#^{2

3

4}, Francesco Schettini^#^{5

6

7}

¹ Clinic Institute of Gynecology, Obstetrics and Neonatology, Hospital Clinic of Barcelona, Barcelona, Spain.
² Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.
³ Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
⁴ Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
⁵ Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain. schettini@clinic.cat.
⁶ Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain. schettini@clinic.cat.
⁷ Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. schettini@clinic.cat.

^# Contributed equally.

No abstract available

Comment on

Nonsentinel Axillary Lymph Node Status in Clinically Node-Negative Early Breast Cancer After Primary Systemic Therapy and Positive Sentinel Lymph Node: A Predictive Model Proposal.
Cebrecos I, Mension E, Alonso I, Castillo H, Sanfeliu E, Vidal-Sicart S, Ganau S, Vidal M, Schettini F. Cebrecos I, et al. Ann Surg Oncol. 2023 Aug;30(8):4657-4668. doi: 10.1245/s10434-023-13231-x. Epub 2023 Feb 21. Ann Surg Oncol. 2023. PMID: 36809608 Free PMC article.

1. Mamounas EP, Kuehn T, Rutgers EJT, von Minckwitz G. Current approach of the axilla in patients with early-stage breast cancer. Lancet. 2017;S0140–6736(17):31451–4. https://doi.org/10.1016/S0140-6736(17)31451-4 . - DOI
1. Cebrecos I, Mension E, Alonso I, et al. Nonsentinel axillary lymph node status in clinically node-negative early breast cancer after primary systemic therapy and positive sentinel lymph node: a predictive model proposal. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13231-x . - DOI - PubMed - PMC
1. Alliance for Clinical Trials in Oncology. Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy. Available at https://clinicaltrials.gov/ct2/show/NCT01901094 . Accessed 9 Feb 2023.